THE USE OF BOTULINUM TOXIN INJECTION IN THE MANAGEMENT OF MYOFASCIAL PAIN DYSFUNCTION SYNDROME
osama, N., Attia, S., Farmawy, M., Nemmat, A., Shalash, M. (2017). THE USE OF BOTULINUM TOXIN INJECTION IN THE MANAGEMENT OF MYOFASCIAL PAIN DYSFUNCTION SYNDROME. EKB Journal Management System, 63(Issue 4 - October (Oral Surgery)), 3069-3075. doi: 10.21608/edj.2017.76102
Nashwa osama; Sayed Attia; Mohamed Farmawy; Amany Hussien Nemmat; Mahmoud Shalash. "THE USE OF BOTULINUM TOXIN INJECTION IN THE MANAGEMENT OF MYOFASCIAL PAIN DYSFUNCTION SYNDROME". EKB Journal Management System, 63, Issue 4 - October (Oral Surgery), 2017, 3069-3075. doi: 10.21608/edj.2017.76102
osama, N., Attia, S., Farmawy, M., Nemmat, A., Shalash, M. (2017). 'THE USE OF BOTULINUM TOXIN INJECTION IN THE MANAGEMENT OF MYOFASCIAL PAIN DYSFUNCTION SYNDROME', EKB Journal Management System, 63(Issue 4 - October (Oral Surgery)), pp. 3069-3075. doi: 10.21608/edj.2017.76102
osama, N., Attia, S., Farmawy, M., Nemmat, A., Shalash, M. THE USE OF BOTULINUM TOXIN INJECTION IN THE MANAGEMENT OF MYOFASCIAL PAIN DYSFUNCTION SYNDROME. EKB Journal Management System, 2017; 63(Issue 4 - October (Oral Surgery)): 3069-3075. doi: 10.21608/edj.2017.76102

THE USE OF BOTULINUM TOXIN INJECTION IN THE MANAGEMENT OF MYOFASCIAL PAIN DYSFUNCTION SYNDROME

Egyptian Dental Journal
Article 6, Volume 63, Issue 4 - October (Oral Surgery), October 2017, Pages 3069-3075    PDF (1.02 M)
Document Type: Original Article
DOI: 10.21608/edj.2017.76102
Authors
Nashwa osama1; Sayed Attia2; Mohamed Farmawy3; Amany Hussien Nemmat4; Mahmoud Shalash4
1Oral Surgery and Medicine Department, National Research Centre, Egypt
2Professor of Oral & Maxillofacial Surgery, Cairo University
3Lecturer of oral & Maxillofacial Surgery, Cairo University
4Oral Surgery and Medicine Department, National Research Centre, Egypt.
Abstract
Objectives: To evaluate the short-term effect of the botulinum toxin, type A (BTX-A) injection for the treatment of myofascial pain dysfunction syndrome.
Materials & Methods: Foueteen female patients suffering from myofascial pain dysfunction syndrome were included in this study. For all patients both the masseter and temporalis muscles were injected once with 20-30 Units of BTX-A respectively and followed up for three months. Follow up included clinical assessment of maximal inter-incisal opening, range of lateral movement and visual analogue scale for pain. Electromyography (EMG) images were ordered pre-operatively and at the end of 3 months’ period to quantify the changes in muscle activity.
Results: Results of the present study showed resolution of pain in all patients upon completing the follow up period.
Conclusion: Within the limits of this study BTX-A can be used effectively for the treatment of myofacial pain dysfunction syndrome.
Statistics
Article View: 218
PDF Download: 382